Connect with us

TechCrunch

FindAir is a smart inhaler

FindAir is digitizing asthma therapy with smart inhaler technology. The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education. TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech…

Published

on

FindAir is digitizing asthma therapy with smart inhaler technology.

The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education.

TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.

Continue Reading
Advertisement
9 Comments

9 Comments

  1. Abhishek Rao Chimbili

    October 27, 2019 at 4:51 pm

    That is the most useless thing I’ve ever seen.

  2. Brandon S.

    October 27, 2019 at 4:52 pm

    You are supposed to use a spacer. The inhaler alone is not good. Not to mention there are some inhalers that already track the number of uses. This is pointless.

  3. Greg Nulik

    October 27, 2019 at 7:21 pm

    Hope the sensor supports a full dosage.

  4. polyannamoonbeam

    October 27, 2019 at 10:39 pm

    Not enough info …sensor tells you what your trigger was…? How? Blood prick analysis? Heartrate? Allergen analysis? Doctors are now instructed to ration patients to one Ventolin a month, two if you argue at length. There is no science to back up patients self diagnosed need for more, doctors differ on what is sufficient, how to measure severity and are often punitive/ biased against smokers. Many patients become resistant to their Ventolyn due to misuse, long term use.. tracking usage doesnt tell you whether patient needed to use more or less puffs for each event or just misused due to poor technique….severe attacks are not managed by Ventolin. Steroids,adrenalin, intravenous meds, full mask vaporised meds- we use all in winter for son.

  5. Pinitrius

    October 27, 2019 at 11:34 pm

    Being an allergist I was interested to see what this was about… But no! It gives some information about patient adherence to the treatment but as with many products/service it is trying to force a subscription down patients throat without providing real long term value! And the product itself is rendered useless after 12 months due to the non-removable battery!

    To me it is just a gimmick the way they chose to make it and charge for it! Sorry…

  6. TechPimp

    October 28, 2019 at 1:51 am

    I didn’t understand what the heck it does?

  7. Gezaei Teklay

    October 28, 2019 at 2:09 am

    I hope it is helpful for asthma

  8. Arthur

    October 28, 2019 at 9:12 am

    So it counts how many times you use an inhaler a day and displays it on an app?

  9. takeonparis

    October 29, 2019 at 12:15 am

    This is the dumbest interview I’ve ever seen. He doesn’t even bother to ask: “So what does your product DO?” Like what in the actual hell…

Leave a Reply

Your email address will not be published. Required fields are marked *

Science & Technology

Mark Zuckerberg Has a Question for AI Doomers

Mark Zuckerberg dropped a 6,500-word letter detailing his vision for “The Path to a Positive AI Future.” Equity takes a closer look at one of his arguments: If you believe AI could eliminate most jobs and humanity’s relevance, why rush to build that future?

Published

on

Mark Zuckerberg dropped a 6,500-word letter detailing his vision for “The Path to a Positive AI Future.”

Equity takes a closer look at one of his arguments: If you believe AI could eliminate most jobs and humanity’s relevance, why rush to build that future?

Continue Reading

Science & Technology

Alignment Is Worth More Than a Bigger Check

More money isn’t always better. Manan Mehta from Unshackled Ventures breaks down why investors who understand your story, your purpose, and why you’re building can be far more valuable than a bigger check from someone who’s misaligned. Check out the full interview on Build Mode:

Published

on

More money isn’t always better. Manan Mehta from Unshackled Ventures breaks down why investors who understand your story, your purpose, and why you’re building can be far more valuable than a bigger check from someone who’s misaligned.

Check out the full interview on Build Mode:

Continue Reading

Science & Technology

Is Meta’s AI really ‘for everyone’?

Meta says AI should be “for everyone.” But is its AI actually accessible to everyone? The Equity podcast crew digs into the gap between Mark Zuckerberg’s vision and the hardware actually required to run Meta’s new open-weight model.

Published

on

Meta says AI should be “for everyone.” But is its AI actually accessible to everyone?

The Equity podcast crew digs into the gap between Mark Zuckerberg’s vision and the hardware actually required to run Meta’s new open-weight model.

Continue Reading

Trending